“`html
WASHINGTON, February 6, 2026 – Hims & Hers will halt sales of a compounded version of Novo Nordisk’s weight-loss medication, following calls for an inquiry into potential federal law violations.The company had been marketing the drug as a lower-cost alternative.
Cheaper Wegovy Alternative Draws Scrutiny
The telehealth company faced backlash and regulatory pressure after launching a compounded version of the popular weight-loss drug.
What is drug compounding? It’s the practice of combining, mixing, or altering ingredients to create a medication tailored to an individual patient’s needs. While legal in certain circumstances-like drug shortages-mass production of compounded versions of approved drugs raises important safety and legal concerns.
Hims launched the compounded drug earlier this week, pricing it at $49 per month. This immediately drew criticism from novo Nordisk, which introduced the oral version of its Wegovy treatment last month at a price range of $149 to $299 monthly. The mass production of copies of a brand-name drug is generally permissible onyl when the original drug is in short supply.
The Food and Drug Governance quickly responded, stating it would take “decisive steps” to prevent companies like Hims from broadly marketing unapproved, compounded GLP-1 drugs. On Friday, the Department of Health and Human Services escalated the matter, requesting a Department of Justice investigation into hims’ practices.
Did you know? – Compounded drugs are not FDA-approved. This means they haven’t undergone the same safety and efficacy testing as commercially manufactured medications,potentially posing risks to patients.
Regulatory Concerns Over Compounded Medications
The FDA’s concern centers around the potential risks associated with compounded drugs that haven’t undergone the same rigorous review as FDA-approved medications. Compounding pharmacies are intended to address individual patient needs, not to mass-produce alternatives to commercially available drugs.
Why did this happen? Hims & Hers began selling a compounded version of Novo Nordisk’s weight-loss medication, Wegovy, at a considerably lower price point ($49/month vs.$149-$299). Who was involved? Hims & Hers, Novo Nordisk, the Food and Drug Administration (FDA), and the Department of Justice (DOJ). What occurred? The FDA and HHS took issue with Hims’ mass production and marketing of a compounded drug outside of legally permissible circumstances (like drug shortages). How did it end? Hims & Hers halted sales of the compounded drug following the regulatory pressure and a DOJ investigation request.
Pro tip – Before using any compounded medication, discuss the risks and benefits with your doctor. Ensure the compounding pharmacy is licensed and follows strict quality control standards.
Reader question – Do you think telehealth companies should be allowed to offer compounded medications as a way to lower healthcare costs? What safeguards would need to be in place?
- Hims & Hers has stopped selling its compounded version of Novo Nordisk’s weight-loss pill.
- The move comes after investigations were launched by health officials.
- Mass production of compounded drugs is typically only allowed during shortages
